Nuclear Medicine Market Report to 2031: Visiongain Research Inc

/EIN News/ — Visiongain has released a new report on Nuclear Medicine Market Report 2021-2031: Forecast by Type (Diagnostic (SPECT – Technetium, PET- F-18), by Therapeutic (Beta Emitters – I-131, Alpha Emitters, Brachytherapy – Y-90)), by Application (Oncology, Cardiology). PLUS, Profiles of leading pharmaceutical contract manufacturing companies and regional and national market analysis. MORE, COVID-19 Recovery Scenarios.

Nuclear medicine/radiopharmaceuticals are radioactive compounds administered to the patient and monitored via specific imaging devices for diagnostic and therapeutic purposes.

Download exclusive sample report @ https://www.visiongain.com/report/nuclear-medicine-market-2021/#download_sampe_div

A radiopharmaceutical is a drug that can be used for diagnostic or therapeutic purposes. It consists of a radioisotopic bond to an organic molecule. The organic molecule transports the radioisotope to specific organs, tissues or cells.

Short-range particle-emitting radioisotopes are used in therapy because of their ability to lose all their energy over a very short distance. This property is used for therapeutic purposes such as the destruction of cancer cells in the treatment of pain in palliative care for bone cancer or arthritis. These isotopes remain in the body longer than the imaging ones, this is intentional in order to increase the effectiveness of the treatment.

Impact of COVID-19 on the Nuclear Medicine/Radiopharmaceutical Market

The nuclear drug / radiopharmaceutical markets are likely to grow due to the Covid 19 pandemic.

Due to the pandemic, hospitals are operating with overcapacity. The threat is to patients with heart disease and cancers, therefore patients are likely to be diverted to nuclear medicine/radiopharmaceuticals.

Market factors

Market growth can be divided into factors such as increasing incidence and occurrence of cancers and heart problems.

Market constraints

Radiopharmaceuticals are reducing their potential adoption as hospital budget cuts and high equipment prices are expected to limit the market growth at some point.

Get a detailed table of contents @ https://www.visiongain.com/report/nuclear-medicine-market-2021/#download_sampe_div

Market opportunities

The use of radiopharmaceuticals in neurological applications paves the way for the growth of the nuclear drugs market.

Competitive landscape

The nuclear medicine market works for the development of new technologies for the production of radioisotopes, government funding and corporate initiatives in the respected country. Major nuclear drug manufacturing companies include: Cardinal Health (US), GE Healthcare (US), Curium (France), Lantheus Medical Imaging (US), Bayer AG (Germany), Bracco Imaging (Italy) ), Eczacýbaþý-Monrol Nuclear Products (Turkey), Nordion (Canada), Advanced Accelerator Applications (France), NTP Radioisotopes (South Africa), JSC Isotope (Russia), NorthStar Medical Radioisotopes (USA), Eckert & Ziegler ( Germany), Jubilant DraxImage (Canada), PharmaLogic (USA), Institute of Isotopes Co., Ltd. (Hungary), Sinotau Pharmaceuticals (China), Isotopia Molecular Imaging Limited (Israel), SHINE Medical Technologies (USA) and Global Medical Solutions (USA).

RECENT DEVELOPMENTS

  • In 2019, Curium acquired MAP Medical, which will help it strengthen its geographical presence in Europe with direct access to the Nordic and Baltic countries.
  • In 2019, Eczacýbaþý-Monrol and Telix Pharmaceuticals Limited (Australia) signed a manufacturing and distribution agreement. According to the signed contract, Eczacýbaþý-Monrol will work as a radiopharmaceutical production partner and distributor in Turkey, the Middle East and North Africa for Telix.
  • In 2019, Curium (France) and NRG (Netherlands) signed a contract for the production of Molybdenum-99.

Find quantitative and qualitative analyzes with independent predictions. Receive insights that only our report contains, staying informed with this valuable business intelligence.

To access the data contained in this document please email contact [email protected]

Information found nowhere else
With our new report title, you’re less likely to fall behind in your knowledge or miss opportunities. See how our work could benefit your research, analysis and decisions. The Visiongain study is aimed at anyone who needs business analysis for the nuclear medicine market and leading companies. You will find data, trends and forecasts.

Find more Visiongain research reports at New pharmaceutical technologies; click on the following links:

Do you have any custom requirements that we can help you with? Do you need specific information about a specific country, geographic region, market segment or company? contact us todaywe can discuss your needs and see how we can help: [email protected]

About Visiongain

Visiongain is one of the fastest growing and most innovative independent market intelligence companies. The company publishes hundreds of market research reports which it adds to its extensive portfolio every year. These reports offer in-depth analysis of 18 industries worldwide. The reports cover a 10-year forecast, are hundreds of pages long, with in-depth market analysis and valuable competitive intelligence data. Visiongain works across a range of vertical markets, which can currently influence each other, these markets include automotive, aviation, chemical, cyber, defence, energy, food and beverage, materials, packaging, pharmaceuticals and utilities. Our customized and syndicated market research reports mean you can have tailored market intelligence tailored to your own business needs.

Contact:

Catherine Walker
PR at Visiongain Inc.
Tel: + 44 0207 336 6100
USA Tel: + 1 718 682 4567
Tel EU: + 353 1 695 0006
Toll Free: 00-1-646-396-5129
Email: [email protected]
Web: https://www.visiongain.com
Follow us: LinkedIn | Twitter

SOURCE Visiongain Limited.

main logo

Comments are closed.